Today: Feb 14, 2025

Healthtech Amber Therapeutics Secures $100M Series A Funding

8 months ago

Amber Therapeutics, a pioneering medical technology startup based in London, has successfully closed a $100 million (£78 million) Series A funding round.

This investment aims to accelerate the development of its innovative adaptive neuromodulation therapy, Amber-UI, designed to treat mixed urinary incontinence (MUI).

Founded in 2021, Amber Therapeutics has quickly emerged as a leader in the medical technology field.

Its flagship product, Amber-UI, represents a major advancement in the treatment of MUI. This condition, which affects millions of women globally, has long lacked effective therapeutic options.

Amber-UI is distinguished as the first fully implantable adaptive neuromodulation therapy currently in clinical development for MUI, targeting the pudendal nerve through minimally invasive surgery.

“Securing this significant financing round from such a prestigious group of US and UK investors is a huge validation of our therapy value proposition and the quality of the team we have built,” said Aidan Crawley, CEO of Amber Therapeutics.

“This funding will enable us to execute the critical next phase of our strategy to take Amber-UI to US regulatory approval and fulfill our mission of making this breakthrough therapy available to the millions of women suffering from mixed urinary incontinence.”

The Series A funding round was led by New Enterprise Associates, with participation from a robust investment syndicate including F-Prime Capital, Lightstone Ventures, and Intuitive Ventures, alongside existing investors Oxford Science Enterprises and 8VC.

This diverse group of investors highlights the broad-based confidence in Amber Therapeutics’ innovative approach and the potential impact of its technology.

“We believe Amber Therapeutics has the potential to become the first-ever approved therapy for a significantly under-addressed patient population,” stated Tiffany Le, Principal at New Enterprise Associates.

“This technology is the culmination of decades of research, and we are proud to support such an innovative therapy that could provide an effective treatment for an often overlooked and under-discussed condition that affects so many women worldwide.”

With this fresh injection of capital, Amber Therapeutics is poised to commence pilot studies in Europe and the United States, marking a crucial step toward clinical validation and regulatory approval.

These studies will be instrumental in demonstrating the efficacy and safety of Amber-UI, paving the way for broader market access and ultimately improving the quality of life for women affected by MUI.

Amber-UI is the first fully implantable adaptive neuromodulation therapy in clinical development for women with MUI, targeting the pudendal nerve through a novel, minimally invasive surgical procedure.

The proceeds of the financing will be used to fund the development of Amber-UI through pilot and pivotal studies towards regulatory approval in the US.

Urinary incontinence (UI) is a debilitating medical condition that affects millions of women globally.

Many of these women experience symptoms of both urge incontinence (urgent and uncontrollable bladder leaks) and stress incontinence (bladder leaks during physical activity or exertion).

However, there is no singular therapy available to treat patients with these MUI symptoms

Fabrice Iranzi

Journalist and Project Leader at LionHerald, strong passion in tech and new ideas, serving Digital Company Builders in UK and beyond
E-mail: iranzi@lionherald.com